Navigation Links
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Date:3/26/2008

study showed highly significant increases in physician confidence in their ability to identify structural abnormalities, the number of pancreatic duct segments visualized and improvement in the overall quality of the MRI images.

RG1068 is a synthetic version of human secretin, a natural gastrointestinal hormone involved in the process of digestion. Secretin has been used for many years by gastroenterologists in combination with endoscopy, an invasive procedure to evaluate and treat diseases of the pancreas and gallbladder. There are risks associated with the use of endoscopy, which have generated interest in the development of safer non-invasive tests to diagnose gastrointestinal disorders. The use of secretin in combination with a non- invasive procedure such as MRI can improve the detection of abnormalities and increase the diagnostic quality of the MRI image of the pancreas. The use of MRI is attractive for patient care as it can obviate the need for more risky invasive procedures.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that s
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that its ... for the second quarter 2015 of $0.03 per share ... $0.03 per share will be paid on June 19, ... June 12, 2015.  The ex-dividend date for the quarterly ...
(Date:5/21/2015)... Mass. , May 21, 2015  (MUSE ... the Electronic Health Record (EHR) is invaluable in ... Though EHRs are now a requirement and mainstream ... and continuously into the EHR is gaining traction ... Exchange), William Holmes, RN, Site Project Manager & ...
(Date:5/21/2015)... 21. Mai 2015 Dipexium ... ein Unternehmen für Arzneimittel im fortgeschrittenen ... und Vermarktung von Locilex® (Pexiganan-Creme 0,8 %) ... eine wissenschaftliche Posterpräsentation an, welche das ... vorstellt, OneStep-1 und OneStep-2, in der ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... 2011 Talyst announces AutoPharm® Mobile, an Apple ... mobile application can be conveniently accessed on an ... and control across the health system. ... have real-time access to medication inventory throughout the ...
... Reportlinker.com announces that a new market research ... Global Medical Laser Systems Industry ... This report analyzes the worldwide markets ... by the following Product Segments: Surgical Lasers, ...
Cached Medicine Technology:Talyst Releases AutoPharm Mobile 2Global Medical Laser Systems Industry 2
(Date:5/22/2015)... (PRWEB) May 22, 2015 Hands On ... June 17, 2015, the Annual One Day Sale ... 2007, Hands On HCMT offers drastically reduced certificates one day ... estheticians have enough sessions, through what used to be the ... wonderful for the community as well. This once a year ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the ... offering some tips to help promote safe travel. , According ... 383 traffic fatalities this Memorial Day weekend. Amica is sharing ... Safety Association: , , Always wear ... a seatbelt, whether they’re driving or riding along as a ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 According to ... hub for drug related death, totaling almost 2,500 confirmed drug ... reported by state officials, totals 2,489 deaths stemming from legal ... out, Pennsylvania loses seven people every day to fatal overdoses ... been singled out as one of the most rife with ...
(Date:5/22/2015)... A Phase 3 French study, ... of Clinical Oncology (ASCO)’s annual meeting at the ... those patients who received bevacizumab in addition to ... (Avastin® Genentech, Inc.) is an antibody that blocks ... routinely used to treat many other cancers, including ...
(Date:5/22/2015)... Steven Winter Associates (SWA) Vice President and ... by Consulting-Specifying Engineer (CSE) magazine as a young leader ... the May/June issue of the publication. , This award ... and younger who have, and continue to make significant ... other areas of their professional and personal endeavors. Candidates ...
Breaking Medicine News(10 mins):Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2
... of deprivation from being in poverty and poor health. ... heart disease is potentially denying// life saving preventive treatment ... ahead of print in the journal Heart. ,A ... allocated "primary preventive" treatment, is currently calculated using the ...
... worried over the increasing malfunction of heart devices, which ... 1990 and 2002. ,The Food and Drug Administration ... physicians and heart-device manufacturers recently, which found that 4,225 ... of defibrillators failed in the previous 10 years, reports ...
... may face difficulty in keeping dental care appointments as ... memories of the abuse experience and such victims may ... of a study reported in the latest issue of ... ,The study, conducted by a team of Canadian researchers, ...
... has shown that there are few clinical comparisons available ... seeking the best individual drug for their children with ... to help make that choice. ,There are few ... relatively large variety of drugs prescribed for ADHD and ...
... is certainly one of the risk factors associated with ... Time and again, many studies have established significant relationship ... World Heart Day fast approaching may be it is ... of World Heart Day (September 25th) is “Healthy Weight, ...
... possible using anti-nicotine vaccine. ,Are you a chain smoker ... vaccine could help., ,Swiss scientists have developed a ... the smoker // with no kick, reports news portal ... by Swiss pharmaceutical firm Cytos, works by building antibodies ...
Cached Medicine News:Health News:Deprivation Can Cause Undetected Heart Problems 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2Health News:Clinical Comparisons Between ADHD Drugs Are Less 2
... sized High-Throughput Submarine Systems are designed ... from microtitre plates. Analyze high numbers ... oligos or PCR products simultaneously. The ... accuracy and speed with additional savings ...
... Dodeca cell runs up to 12 mini ... minutes. Handcast gels can be poured 12 ... 485 gradient former and Mini-PROTEAN 3 multi-casting ... reproducibility. Alternatively, Ready Gel precast gels offer ...
... Criterion Dodeca cell, a component of the Criterion ... to 12 Criterion gels in a single run. ... 8.7 cm) than the traditional mini gel. They ... give you the optimal combination of separation and ...
... runs up to 12 mini gels under ... gels can be poured 12 at a ... former and Mini-PROTEAN 3 multi-casting chamber, eliminating ... Ready Gel precast gels offer the convenience ...
Medicine Products: